|
**Overview**: Glucose Fasting Postprandial Panel**Introduction**: The Glucose Fasting Postprandial Panel is a diagnostic tool designed to assess glucose levels using plasma samples. In India, fasting and postprandial glucose are key for diabetes diagnosis/monitoring (~77 million adults affected), with postprandial hyperglycemia common in type 2 diabetes. High morbidity from under-testing in rural/low-SES patients with polyuria or fatigue, limited labs, delayed lifestyle/metformin leading to complications. Per endocrinology practices aligned with ICMR and RSSDI guidelines, the test employs spectrophotometry for fasting and postprandial glucose over 1-2 days with high accuracy, valuable for opportunistic screening and control assessment. This diagnostic falls under glucose screening and targets patients with diabetes risk or symptoms, addressing accurate detection to guide therapy adjustment. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise glucose profiling and reducing complications. Its plasma-based approach ensures reliable measurement.**Other Names**: Glucose FPP Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: FPG/PPG standard; in India, used in diabetes clinics.**Purpose**: The test assesses 2 parameters including fasting glucose to guide glucose level evaluation, detect hyperglycemia, inform management.**Test Parameters**: 1. Fasting Glucose, 2. Postprandial Glucose.**Pretest Condition**: Fasting 10-12 hours required; patients should report symptoms or risk factors.**Specimen**: 3 mL plasma in NaF tube (multiple draws), transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on symptoms, family diabetes, meal timing.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated hyperglycemia including complications, benefits of screening, and minimal discomfort from multiple draws.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or meal non-compliance can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated fasting/postprandial indicates diabetes/prediabetes, necessitating specialist input.**Specialist Consultation**: Diabetologists should be consulted for management.**Additional Supporting Tests**: HbA1c for confirmation.**Test Limitations**: Postprandial timing critical; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, Diabetes Studies India 2023. |
